Events & Presentations

Jul 12, 2021 8:15 AM EDT	CDX-0159 Phase 1b Study Results in Cold Urticaria and Symptomatic Dermographism Late Breaking Presentation at EAACI 2021 Listen to webcast View Presentation 657.5 KB

Jul 12, 2021
8:15 AM EDT

CDX-0159 Phase 1b Study Results in Cold Urticaria and Symptomatic Dermographism Late Breaking Presentation at EAACI 2021

Mar 29, 2021 7:45 AM EDT	Celldex Phase 1b CIndU Interim Data Update Listen to webcast View Presentation 496.6 KB Press Release 48.6 KB

Mar 29, 2021
7:45 AM EDT

Celldex Phase 1b CIndU Interim Data Update

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

Investor Relations Contacts

Events & Presentations

About us

Our Pipeline